<?xml version="1.0" encoding="UTF-8"?>
<ref id="CR8">
 <label>8.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Pernas</surname>
    <given-names>S</given-names>
   </name>
   <name>
    <surname>Tolaney</surname>
    <given-names>SM</given-names>
   </name>
  </person-group>
  <article-title>HER2-positive breast cancer: New therapeutic frontiers and overcoming resistance</article-title>
  <source>Ther. Adv. Med. Oncol.</source>
  <year>2019</year>
  <volume>11</volume>
  <fpage>1758835919833519</fpage>
  <pub-id pub-id-type="doi">10.1177/1758835919833519</pub-id>
  <?supplied-pmid 30911337?>
  <pub-id pub-id-type="pmid">30911337</pub-id>
 </element-citation>
</ref>
